Shares in healthcare services group Uniphar jumped today after it said it had performed in line with expectations for 2024 at an earnings per share level, while delivering normalised free cashflow conversion above its medium-term guidance.
In a trading update for the year, Uniphar said it achieved over 8% growth in organic gross profit and 12% adjusted EPS growth.
The group continues to maintain a strong liquidity position, it added.
Uniphar said it is well positioned to deliver organic gross profit growth across all divisions and, consistent with its medium-term targets.
It also said that merger and acquisition actitivty continues to play an important role in Uniphar's growth strategy.
"The group maintains a disciplined approach to capital allocation, while managing an active pipeline of acquisition opportunities to further enhance the group's growth potential," it added.
Ger Rabbette, Uniphar Group's chief executive, said that 2024 was a great year for Uniphar, with all of its divisions contributing to excellent organic growth.
"The results show the positive impact that our strategy is having on our ability to grow at pace organically. Based on our 2024 results, we are even more confident of reaching our €200m EBITDA target over the medium-term, with at least 80% of our growth being organic," the CEO added.
Uniphar is due to publish its final results for the year ended December 31, 2024 on February 25.
Its shares moved higher in Dublin trade today.
